<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GLUCAGON</span><br/>(gloo'ka-gon)<br/><span class="topboxtradename">GlucaGen<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg powder for injection</p>
<h1><a name="action">Actions</a></h1>
<p>Polypeptide hormone produced by alpha cells of islets of Langerhans. Stimulates uptake of amino acids and their conversion
         to glucose precursors.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Promotes lipolysis in liver and adipose tissue with release of free fatty acid and glycerol, which further stimulates ketogenesis
         and hepatic gluconeogenesis. Action in hypoglycemia relies on presence of adequate liver glycogen stores.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Emergency treatment of severe hypoglycemic reactions in diabetic patients who are unconscious or unable to swallow food or
         liquids and in psychiatric patients receiving insulin shock therapy. Also radiologic studies of GI tract to relax smooth muscle
         and thereby allow finer detail of mucosa; to diagnose insulinoma.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>GI disturbances associated with spasm, cardiovascular emergencies, and to overcome cardiotoxic effects of beta blockers, quinidine,
         tricyclic antidepressants; as an aid in abdominal imaging.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to glucagon or protein compounds. Safe use during pregnancy (category B) or lactation is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Insulinemia, pheochromocytoma.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypoglycemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/IV/SC</span> 0.51 mg, may repeat q520 min if no response for 12 more doses<br/><span class="rdage">Child:</span> <span class="rdroute">IM/IV/SC</span> 0.025 mg/kg (max: 1 mg/dose), may repeat q520 min if no response for 12 more doses<br/><span class="rdage">Neonate:</span> <span class="rdroute">IM/IV/SC</span> 0.3 mg/kg (max: 1 mg)<br/><br/><span class="indicationtitle">Insulin Shock Therapy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/IV/SC</span> 0.51 mg usually 1 h after coma develops, may repeat in 25 min if no response<br/><br/><span class="indicationtitle">Diagnostic Aid to Relax Stomach or Upper GI Tract</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/IV/SC</span> 0.252 mg 10 min before the procedure<br/><br/><span class="indicationtitle">Diagnostic Aid for Examination of Colon</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/IV/SC</span> 2 mg 10 min before the procedure<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p> 			Note: 1 mg  1 unit 		</p><span class="adminroutetype">Subcutaneous/</span><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Dilute 1 unit (1 mg) of glucagon with 1 mL of diluent supplied by manufacturer.</li>
<li>Use immediately after reconstitution of dry powder. Discard any unused portion.</li>
<li> 				Note: Glucagon is incompatible in syringe with any other drug. 			</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Prepare as noted above. Do not use a concentration &gt;1 unit/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give 1 unit or fraction thereof over 1 min. May be given through a Y-site D5W (not NS) infusing.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> Sodium chloride. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store unreconstituted vials and diluent at 20°25° C (68°77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> Nausea and vomiting. <span class="typehead">Body as a Whole:</span> Hypersensitivity reactions. <span class="typehead">Skin:</span> <span class="speceff-life">Stevens-Johnson syndrome</span> (erythema multiforme). <span class="typehead">Metabolic:</span> Hyperglycemia, hypokalemia. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 520 min. <span class="typehead">Peak:</span> 30 min. <span class="typehead">Duration:</span> 11.5 h. <span class="typehead">Metabolism:</span> Metabolized in liver, plasma, and kidneys. <span class="typehead">Half-Life:</span> 310 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Be prepared to give IV glucose if patient fails to respond to glucagon. Notify physician immediately.</li>
<li> 							Note: Patient usually awakens from (diabetic) hypoglycemic coma 520 min after glucagon injection. Give PO carbohydrate as
            soon as possible after patient regains consciousness. 						
         </li>
<li> 							Note: After recovery from hypoglycemic reaction, symptoms such as headache, nausea, and weakness may persist. 						</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li> 							Note: Physician may request that a responsible family member be taught how to administer glucagon SC or IM for patients with frequent
            or severe hypoglycemic reactions. Notify physician promptly whenever a hypoglycemic reaction occurs so the reason for the
            reaction can be determined. 						
         </li>
<li>Review package insert and directions (see <small>ADMINISTRATION</small>).
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>